002022.SHE Shanghai Kehua Bio-Engineering Co Ltd
- Market cap
- CNY 2.76B
- P/E
- -
- P/B
- 1.08x
- ROE
- -8.5%
- Dividend yield
- 0.56%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002022.SHE undervalued?
Graham numberThe Graham number of Shanghai Kehua Bio-Engineering Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Kehua Bio-Engineering Co Ltd fundamental analysis
No fundamental analysis for Shanghai Kehua Bio-Engineering Co Ltd yet.
Shanghai Kehua Bio-Engineering Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Kehua Bio-Engineering Co Ltd
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry …
Full company profileShanghai Kehua Bio-Engineering Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Kehua Bio-Engineering Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.40B | 1.59B | 1.99B | 2.41B | 4.16B | 4.85B | 6.97B | 2.43B | 1.76B | 1.64B | 1.69B |
| Gross Profit | 576M | 651M | 813M | 1.06B | 2.38B | 2.65B | 3.56B | 945M | 512M | 576M | 636M |
| Operating Income | 256M | 261M | 298M | 332M | 1.36B | 1.64B | 2.07B | -179M | -727M | -338M | -115M |
| EBITDA | 339M | 341M | 399M | 477M | 1.52B | 1.85B | 2.27B | 50.8M | -471M | -550M | -147M |
| Net Income | 232M | 218M | 208M | 202M | 675M | 850M | 972M | -234M | -641M | -732M | -212M |
| EPS | 0.45 | 0.42 | 0.40 | 0.39 | 1.32 | 1.60 | 1.82 | -0.46 | -1.27 | -1.42 | -0.40 |
| Balance Sheet | |||||||||||
| Total Assets | 2.32B | 2.72B | 3.50B | 3.70B | 5.98B | 6.96B | 8.81B | 6.81B | 5.24B | 4.64B | 4.25B |
| Total Liabilities | 422M | 636M | 1.07B | 1.01B | 2.08B | 1.82B | 2.96B | 1.82B | 1.25B | 1.53B | 1.27B |
| Shareholders' Equity | 1.84B | 2.00B | 2.18B | 2.36B | 3.14B | 3.87B | 4.81B | 4.03B | 3.35B | 2.64B | 2.50B |
| Cash & Short-term Investments | 748M | 689M | 490M | 442M | 2.15B | 2.64B | 3.47B | 1.95B | 865M | 858M | 587M |
| Total Debt | 38.8M | 51.9M | 366M | 492M | 1.10B | 880M | 866M | 847M | 410M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 281M | 131M | 127M | 249M | 1.37B | 1.08B | 2.15B | -475M | -50.1M | 22.4M | - |
| Capital Expenditure | 103M | 105M | 124M | 140M | 258M | 216M | 428M | 331M | 255M | 139M | 117M |
| Free Cash Flow | 178M | 25.6M | 2.81M | 109M | 1.11B | 863M | 1.73B | -806M | -305M | -117M | -204M |
| Ratios | |||||||||||
| ROE | 12.6% | 10.9% | 9.5% | 8.6% | 21.5% | 22.0% | 20.2% | -5.8% | -19.1% | -27.8% | -8.5% |
| ROA | 10.0% | 8.0% | 5.9% | 5.5% | 11.3% | 12.2% | 11.0% | -3.4% | -12.2% | -15.8% | -5.0% |
| Net Profit Margin | 16.6% | 13.7% | 10.4% | 8.4% | 16.3% | 17.5% | 13.9% | -9.6% | -36.4% | -44.6% | -12.5% |
| Debt to Equity | 0.02x | 0.03x | 0.17x | 0.21x | 0.35x | 0.23x | 0.18x | 0.21x | 0.12x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Kehua Bio-Engineering Co Ltd dividends
- Dividend yield
- 0.56%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 10, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 15.4M | 0.03 | - |
| 2024 | CNY 24.4M | 0.05 | - |
| 2023 | CNY 318M | 0.62 | - |
| 2022 | CNY 33.4M | 0.06 | 3.4% |
| 2021 | CNY 103M | 0.19 | 12.1% |
| 2020 | CNY 33.4M | 0.07 | 4.9% |
| 2019 | CNY 33.4M | 0.07 | 16.5% |
| 2018 | CNY 41.8M | 0.08 | 20.1% |
| 2017 | CNY 71.1M | 0.14 | 32.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 12:10 on May 27, 2010.
Who owns Shanghai Kehua Bio-Engineering Co Ltd
- Insiders 22.62%
- Institutions 2.55%
- Public & others 74.84%
- Shares outstanding 531M
- Free float 406M
Shanghai Kehua Bio-Engineering Co Ltd company profile
- Company name
- Shanghai Kehua Bio-Engineering Co Ltd
- Ticker
- 002022.SHE
- ISIN
- CNE000001KC9
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 5, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,870
- Fiscal year end
- December
- Address
- Caohejing Hi-Tech Park, Shanghai, China, 200233
- Phone
- 86 21 6495 0625
- Website
- skhb.com
About Shanghai Kehua Bio-Engineering Co Ltd
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. Further, it provides instrument products, including biochemical diagnostics, immunological diagnostics, molecular diagnostics, point-of-care testing (POCT), and mass spectrometry, advancing towards automation, digitization, and intelligence. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.
Shanghai Kehua Bio-Engineering Co Ltd management
7- Mr. Ming LiChairman & President · born 1976
- Mr. Xian Feng ZangFinancial Director · born 1975
- Mr. Baogang MiaoVP & Non-Independent Director · born 1976
- Mr. Jiaming LiangVP & Non-Independent Director · born 1982
- Ms. Hongying JinVP & Board Secretary · born 1972
- Mr. Shin Kang HyukVice President · born 1967
- Lei YuAccounting Supervisor